CTR057398__Donohue_and_Associates_-_BAFO.pdf

PDF 9 MB Posted

Attached to
Master Agreement AZ|CTR057398
Contract number
CTR057398
Issued by
Arizona

About this file

This document appears to be a contract or bid response from Michael S. Donohue, Pharm.D., for a state and local contract involving pharmacy consulting services. The document references multiple Arizona-based healthcare facilities, including The Lingenfelter Center, Arizona State Veterans Home, and Sierra Winds, suggesting the contract is primarily focused on pharmaceutical services within Arizona. The file contains various addenda, references, and supplementary materials related to a pharmacy consulting contract, with the primary contact being Michael Donohue as the President.

The contract encompasses pharmacy consulting services with a focus on psychotropic medication utilization and drug interaction analysis. Included in the document are detailed references demonstrating Donohue's experience in providing pharmacy consulting services to long-term care facilities, with references dating back to 2005. The document includes supplementary materials such as drug interaction charts from UpToDate, total psychotropic utilization data comparing state and national averages for 2019-2020, and professional credentials. While specific pricing terms are not explicitly detailed, the document suggests a comprehensive pharmacy consulting service with ongoing support for healthcare facilities in managing medication protocols and interactions.

View the file

Other files

File Type Posted
BPM003308_Donohue_and_Associates_-_BAFO.pdf PDF
CTR057398_-_Contract_Pricing.pdf PDF
CTR057398_Contract_Amendment_3.pdf PDF
CTR057398_Memorandum_for_File_-_Contract_Extension.pdf PDF
RFP_BPM003308_Non_Award_letter_-_American_International_Healthcare_Group_LLC.pdf PDF
RFP_BPM003308_Solicitation_Requirements_Part_1.pdf PDF
1-Attachment B- Questionnaire .docx DOCX document
C.O.I._Donohue___Ass._Consulting_EXP_5.7.2023.pdf PDF
CTR057398_-_Donohue___Associates_-_COI-_Exp._5.7.2024.pdf PDF
RFP_BPM003308_Donohue___Associates_-_Initial.pdf PDF
RFP_BPM003308_Offer_and_Acceptance_-_Donohue_and_Associates.pdf PDF
RFP_BPM003308_SPO_Form_120_-_Robert_Tunila.pdf PDF
RFP_BPM003308_Solicitation_Requirements_Part_2.docx DOCX document
1-ADENIKE (NIKKI) OKODUWA.pdf PDF
1-Attachment C-References 2.pdf PDF
1-Solicition No BPM003308 - AIHG.pdf PDF
2021-05-07_COI_GL_WC.pdf PDF
CTR057398_Contract_Amendment_5.pdf PDF
CTR057398_Donohue_and_Associate_-_Initial.pdf PDF
RFP_BPM003308_Award_Determination.pdf PDF
RFP_BPM003308_Award_Letter_-_Donohue___Associates.pdf PDF
RFP_BPM003308_SPO_Form_120_-_Tim_Bouseman.pdf PDF
1-AIHG-Who we are.pdf PDF
1-Harvinder Bar-PharmD.pdf PDF
CTR057398_Contract_Amendment_1.pdf PDF
CTR057398_Contract_Amendment_2.pdf PDF
CTR057398_Contract_Amendment_4.pdf PDF
Contract_Summary_CTR057398_Pharmacy_Consultants.pdf PDF
RFP_BPM003308_Legal_Advertisement.pdf PDF
RFP_BPM003308_SPO_Form_120_-_Kim_Trotta.pdf PDF
Show all 30

On GovTribe

Work with this file

  • Download the original file
  • Contacts named in this file
  • Similar government files
  • Ask GovTribe AI about this file

Text version

Addendum 1

6/112020 A-1 Michael S Donohue BPS #IND-922931 bps aoard of PhormQO,J Specloltles®

Logged In: Michael S Doi

Payment Successful

Thank you. Your payment is complete and has been assigned the ID: BPS-PMT-201050. Please note this for future reference

The following payments were received/refunded:

Item Date Description

06/12/2020 Credit - Maintenance Fee - Geriatric Pharmacy

2 06/12/2020 Maintenance Fee - Geriatric Pharmacy 2020

We have also sent the payment receipt via email.

Amount

-12.50

125.00

Total: 112.50 https://portalbps.cyzap.neVdzapps/dbzap.bln/apps/assess/webmembers/seoure/manage?webidc:BPS&pToolCode=PMT&pAssessmentlD=&pSave=Ves

Addendum 2

A-2

Addendum 3

A-3

A-3A-3

A-3 A-3A-3

Addendum 4

A-4

A-4

Addendum 5

A-5

Addendum 6

4/5/2021

A-6

Lexicomp® Drug Interactions - UpToDale

Lexicomp® Drug Interactions

Item List

• SEROquel

• Escitalopram

• Levaqufn [DSC]

DSC: Discontinued brand (equivalent product[s] may be available)

NOTE: This tool does not address chemical compatibility related to 1.V. drug preparation or administration.

© 2021 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

CR] Avoid combination [[] Consider therapy modification

4 Results

CC "'] Monitor therapy l-A J No known interaction e·-1 No action needed

: Filter Results by Item v fc'I Escltalopram (QT-prolonging Antidepressants (Moderate Risk))/ Levaqufn [DSC] (QT-prolonging Quinolone

• Antibiotics (Moderate Risk))

!- �__] Escltalopram {QT-prolonging Antidepressants (Moderate Risk)) I SEROquel (QT-prolonging Antipsychotfcs (Moderate

• Risk))

• I [J SEROquel (Antipsychotic Agents)/ Escitalopram (Serotonergic Agents (High Risk))

[§'-] SEROquel (QT-prolonging Antipsychotics (Moderate Risk)) / Levaquin [DSC] (QT-prolonging Quinolone Antibiotics

• (Moderate Risk))

Disclaimer: Readers are advised that decisions regarding drug therapy must be based on the independent Judgment of the clinician, changing information about a drug (eg, as reflected in the literature and manufacturer's most currant product information), and changing medical practices.

https://www.uptodate.com/drug-interactions/?source=responsive_home#di-analyze 1/1

Addendum 7

Addendum 8

AA-8

\-8

Total Psychotropic Utilization

2019 2020 State Avg Nation Avg

Jan 63.1 69.7 57.9 64.7

Feb 62.8 72 57.9 64.7

Mar

Apr

May

Jun

Jul

Aug

Sep

Oct

Nov

Dec

66.5 72.8 57.9 64.7

65.8 76.4 57.9 64.7

78.8 57.9 64.7

78.2 57.9 64.7

80.7 57.9 64.7

74.5 57.9 64.7

74.3 57.9 64.7

70.9 57.9 64.7

76.9 57.9 64.7

72.6 57.9 64.7

I ., . ' • .._,, ,. ..... -- - -····---.-,--. o --• .. .,,., •-••-•n -- - -· -·-. --·. ·---

Total Psychotropic Utilization l 80 : 70 I

,---••••-••--•• --•-•-• ,.,, .. ,, .. .._,__. ,,..__.., ___ ,,-.--•--•-••-.-•••• ........ ,,, •♦ 0 •o•o ... -..-• .--,,•--•·••• ••"'l••U

; 60

I so

40 -·····-····· .. · -· - - ---.. • --· .. - ·-·---· -----·- .... .... _ --

30 -----.. --,·-----------------· --·-·------ "---··- ·-

20 ·-·---- __________ ,.,. ... ,.--.. ···-.. -·-•-"·----···-·-·--· ..... _____ ,_.� ... -- ··-··-- ·

10 ,,,,,,_.,,, ,.,_,. . .,.,. ,,.,,.._,.-,,..,,. """'" ---••�•-"-"• •••••• .. ••••"""""·'"-•••u-.. •• •••"-••· ••• "" - - -• ""

Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

-2019 :;c ·,:·c .. ,2020 -StateAvg -NationAvg

Addendum 9

A-9

Addendum 10

A-10

Addendum 11

A-11

AA-11

A-11

Addendum 12

A-12

Addendum 13

A-12A-13

A-13

Michael Donohue, Pharm.D

President

• The narrative shall provide the appropriate licenses and certificates and describe your knowledge and understanding of the Pharmacy Consultant as stated in section 5 of the Scope of Work.

REFERENCES:

1 Client Company/Address Contact Begin Date End Date

The Lingenfelter Center/1099 Sunrise Avenue, Kingman, Az 86401

The Gardens Care Center

The Legacy Care Center

Kristen OTT‐ President July 2012 Current day

Phone Number Email Address

928‐279‐1780 kott@lingenfeltercenter.com

Materials/goods/equipment provided similar to those described in Solicitation

Yes

Services performed similar to those described in Solicitation

2 Client Company/Address Contact Begin Date End Date

Arizona State Veterans Home Tucson Ernest Harman MD June 2010 Current

928‐899‐0285 Ernestharman634@yahoo.com

3 Client Company/Address Contact Begin Date End Date

Sierra Winds‐ 17300 N 88th Ave, Peoria, AZ 85382

Patricia Chambless June 2005 Current

480‐243‐4968 pchambless393@gmail.com

Blank Page
Blank Page
Blank Page
Blank Page
Blank Page
Blank Page
Blank Page
Blank Page
Blank Page
Blank Page
Blank Page
Blank Page
Blank Page

File details come from the government source that posted it. Updated .